KMPH - KemPharm, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

KemPharm, Inc.

1180 Celebration Boulevard
Suite 103
Celebration, FL 34747
United States
321-939-3416
http://kempharm.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees22

Key Executives

NameTitlePayExercisedYear Born
Dr. Travis C. MickleCo-Founder, Chairman, Pres & CEO530.76kN/A1973
Dr. Sven GuentherExec. VP of R&D364.77kN/A1972
Ms. Christal M. M. MickleCo-Founder and VP of Operations & Product Devel.N/AN/A1979
Mr. R. LaDuane Clifton CPACFO, Sec. & TreasurerN/AN/A1972
Mr. Timothy J. SangiovanniVP & Corp. ControllerN/AN/A1984
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder. It also provides APADAZ, an immediate-release combination product candidate of benzhydrocodone and acetaminophen to treat the short-term management of acute pain. The company has a collaboration agreement with KVK-Tech, Inc. to manufacture and commercialize APADAZ. KemPharm, Inc. was founded in 2006 and is headquartered in Celebration, Florida.

Corporate Governance

KemPharm, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.